Phenibut Reference

Educational, not medical advice reference for Phenibut: Nootropic; regulatory status, evidence posture, source review, and schedule notes. Also…

Plain English

What it is
Phenibut is a Russian-developed compound that acts on a calming brain chemical called GABA. It is not approved by the FDA for any medical use in the United States, though it is sold over the counter as a supplement in many parts of the world.
What people use it for
People talk about it for easing anxiety, feeling more relaxed in social settings, and helping with sleep. In some countries it has been marketed for anxiety and related problems.
What the science shows
The human evidence is thin and comes mostly from older Russian clinical reports, so claims that it sharpens thinking or memory are not well proven. What is clearly documented is that regular use leads to tolerance, meaning it takes more to get the same effect, and to real physical dependence.
The catch
Phenibut is one of the most dependence-prone compounds covered here. Stopping suddenly after regular use can trigger severe withdrawal that may include intense anxiety, hallucinations, psychosis, and seizures, and people have needed emergency or hospital care. Despite being easy to buy, it is far from safe.

Reference summary

Russian-language clinical literature in anxiety / insomnia. Tolerance, physical dependence, and severe withdrawal are extensively documented in case reports.

Regulatory and posture

Categories
Nootropic
Aliases
β-phenyl-γ-aminobutyric acid, Anvifen, Fenibut, Noofen
Evidence posture
human - Not FDA-approved. Controlled in Australia, Lithuania, Hungary, Italy. Severe physical dependence and withdrawal reported in case literature; cold turkey can produce psychosis, seizures, and prolonged dysautonomia. Taper protocols are essential and community guidance is unanimous on this.
Regulatory status
No FDA-approved phenibut drug label. Russian-approved for anxiety / insomnia / asthenia. Controlled substance in Australia (Schedule 9), Lithuania, Hungary, and Italy. Restricted in France. Tolerance and physical dependence are well-documented; severe withdrawal syndromes have been reported in case literature.
Content review status
research reference

Selected public sources

For research and educational purposes only. Not medical advice.